Chinese drugs firm aims to bring down cost of breast cancer treatment
  • Shanghai-based Genor Biopharma plans to seek regulatory approval for coprelotamab to be used in China on late-stage breast cancer patients
  • Genor shares debuted at HK$29.20 in Hong Kong on Wednesday, 21.7 per cent higher than its IPO price of HK$24
7 Oct 2020 - 8:25PM